Showing 1251-1260 of 2145 results for "".
- Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billionhttps://practicaldermatology.com/news/20140528-valeant_pharmaceuticals_to_sell_filler_and_toxin_assets_to_nestle_for_14_billion/2459228/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquis
- Pliaglis Launches in Europehttps://practicaldermatology.com/news/20130502-pliaglis_launches_in_europe/2459551/Nuvo Research Inc. and Galderma Pharma, S.A. launched Pliaglis (lidocaine and tetracaine) Cream 7%/7% in Europe. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, and licenses have been issued in 14 of the 16 European cou
- Galderma Acquires Spirighttps://practicaldermatology.com/news/20121213-galderma_acquires_spirig/2459659/Galderma Pharma S.A. and Spirig Pharma A.G. entered into a definitive agreement under which Galderma will acquire Spirig. Spirig's products treat conditions such as solar damage, skin barrier function impairment, and actinic keratosis. Leading br
- Valeant, Galderma Revise Agreement Termshttps://practicaldermatology.com/news/20121210-valeant_galderma_revise_agreement_terms/2459661/Valeant Pharmaceuticals International, Inc. reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and co
Building Dermatology Patient Relationships with AI Chat and Text Messaging
https://practicaldermatology.com/topics/practice-management/building-dermatology-patient-relationships-with-ai-chat-and-text-messaging/23188/Automated communication tools could actually be the secret to a personal touch.On Mentorship, Open- Mindedness, and Fulfillment: A Chat with Dr. Peter Lio
https://practicaldermatology.com/youngmd-connect/wrap-ups/on-mentorship-open-mindedness-and-fulfillment-a-chat-with-dr-peter-lio/29892/Young MD Connect recently hosted a mentorship session with Dr. Peter Lio to learn from a practicing professional in the field of dermatology in a relaxed “Ask Me Anything” setting. Dr. Lio is a clinical assistant professor of dermatology and pediatrics at Northwestern University and the founding dirThe Colemans: Dermatology as a Father-Son(s) Tradition
https://practicaldermatology.com/topics/feature/colemans-dermatology-father-sons-tradition/26956/The Colemans: Dermatology as a Father-Son(s) Tradition“S or “C” Corporation for Your Practice
https://practicaldermatology.com/topics/practice-management/s-or-c-corporation-for-your-practice/21503/Maximize tax deductions by using both.Journal Club: S. Aureus-Driven AD Exacerbation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-s-aureus-driven-ad-exacerbation/32404/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses a recent Journal of Drugs in Dermatology article about the need for a novel treatment for S. aureus exacerbated atopic dermatitis with Adelaide Hebert, MD.Schachner LA, Andriessen A, Gonzalez ME, Lal K, Hebert AA, EPhysician Spotlight: Jeffrey S. Dover, MD, FRCPC
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-jeffrey-s-dover-md-frcpc/23854/